PODDNasdaqSurgical & Medical Instruments & ApparatusFiscal year ends December 31
INSULET CORP
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 5, 2026
$141.96+0.86 (+0.61%)
Close on Oct 19, 2026
- Market cap
- $9.85B
- P/E (TTM)
- 26.5
- Dividend yield
- –
Insulet statistics
Financials through Jun 30, 2026, price as of Oct 19, 2026, median of Surgical & Medical Instruments & Apparatus companies for comparison
Valuation
| Measure | Insulet | Industry median |
|---|---|---|
| Market Cap | $9.85B | $230.55M |
| Enterprise Value | $10.26B | $202.97M |
| PE Ratio | 26.53 | 31.60 |
| PS Ratio | 3.22 | 3.10 |
| PB Ratio | 6.92 | 3.04 |
| P/TBV Ratio | 7.84 | 4.43 |
| P/FCF Ratio | 33.52 | 27.30 |
| P/OCF Ratio | 19.26 | 22.47 |
Enterprise value
| Measure | Insulet | Industry median |
|---|---|---|
| EV / Sales | 3.36 | 2.91 |
| EV / EBITDA | 16.68 | 19.74 |
| EV / EBIT | 19.89 | 24.80 |
| EV / FCF | 34.93 | 27.89 |
Income (trailing twelve months)
| Measure | Insulet | Industry median |
|---|---|---|
| Revenue | $3.05B | $102.39M |
| Gross Profit | $2.17B | $60.36M |
| Operating Income | $515.80M | -$4.31M |
| Pretax Income | $494.70M | -$2.37M |
| Net Income | $375.30M | -$6.57M |
| EBITDA | $615.10M | -$1.98M |
| EPS (Diluted) | $5.35 | -$0.08 |
Margins
| Measure | Insulet | Industry median |
|---|---|---|
| Gross Margin | 71.1% | 55.2% |
| Operating Margin | 16.9% | -6.04% |
| Pretax Margin | 16.2% | -4.11% |
| Profit Margin | 12.3% | -10.5% |
| EBITDA Margin | 20.1% | -2.67% |
| FCF Margin | 9.62% | 0.02% |
Returns
| Measure | Insulet | Industry median |
|---|---|---|
| Return on Equity (ROE) | 26.0% | -18.2% |
| Return on Assets (ROA) | 11.3% | -13.3% |
| Return on Invested Capital (ROIC) | 21.9% | -3.69% |
| Return on Capital Employed (ROCE) | 21.3% | -9.07% |
Growth
| Measure | Insulet | Industry median |
|---|---|---|
| Revenue Growth (YoY) | 29.4% | 8.85% |
| Net Income Growth (YoY) | 59.0% | 10.5% |
| EPS Growth (YoY) | 64.1% | 10.6% |
| FCF Growth (YoY) | -27.5% | 9.68% |
| Revenue Growth (3Y CAGR) | 27.5% | 7.08% |
| Revenue Growth (5Y CAGR) | 24.5% | 11.8% |
| EPS Growth (3Y CAGR) | 267.7% | 3.11% |
| EPS Growth (5Y CAGR) | 103.4% | 7.64% |
Balance sheet
| Measure | Insulet | Industry median |
|---|---|---|
| Cash & Short-Term Investments | $534.90M | $36.66M |
| Total Debt | $948.40M | $97.65M |
| Net Cash (Debt) | -$413.50M | $3.92M |
| Net Cash Per Share | -$5.96 | $0.28 |
| Equity (Book Value) | $1.42B | $55.33M |
| Book Value Per Share | $20.51 | $2.87 |
| Tangible Book Value | $1.26B | $10.79M |
| Working Capital | $1.10B | $56.72M |
Financial position
| Measure | Insulet | Industry median |
|---|---|---|
| Current Ratio | 2.48 | 2.48 |
| Quick Ratio | 1.51 | 1.53 |
| Debt / Equity | 0.67 | 0.41 |
| Debt / EBITDA | 1.54 | 2.40 |
| Debt / FCF | 3.23 | 3.49 |
| Net Debt / EBITDA | 0.67 | 1.53 |
| Interest Coverage | 8.79 | -1.85 |
Cash flow (trailing twelve months)
| Measure | Insulet | Industry median |
|---|---|---|
| Operating Cash Flow | $511.20M | -$566.22K |
| Capital Expenditures | -$217.50M | -$3.69M |
| Free Cash Flow | $293.70M | -$696.00K |
| FCF Per Share | $4.23 | -$0.02 |
Efficiency
| Measure | Insulet | Industry median |
|---|---|---|
| Asset Turnover | 0.92 | 0.58 |
| Inventory Turnover | 1.90 | 2.21 |
| Revenue Per Employee | $565.46K | $322.92K |
| Profits Per Employee | $69.50K | -$51.88K |
| Employee Count | 5,400 | 185 |
Dividends and yields
| Measure | Insulet | Industry median |
|---|---|---|
| Earnings Yield | 3.81% | -6.88% |
| FCF Yield | 2.98% | -0.45% |
| Buyback Yield | 3.35% | 0.78% |
| Shareholder Yield | 3.35% | 0.80% |
Shares
| Measure | Insulet | Industry median |
|---|---|---|
| Shares Outstanding | 69,354,200 | 44,302,700 |
| Shares Change (YoY) | -4.05% | 3.36% |
| Float | 69,021,400 | 37,462,700 |
| Shares Held by Insiders | 0.48% | 10.5% |
| Shares Held by Institutions | 103.5% | 63.5% |
Taxes
| Measure | Insulet | Industry median |
|---|---|---|
| Income Tax | $119.30M | $1.52M |
| Effective Tax Rate | 24.1% | 18.5% |
Scores
| Measure | Insulet | Industry median |
|---|---|---|
| Graham Number | $49.68 | $35.97 |
| Graham Upside | -65.0% | -57.0% |
| Altman Z-Score | 5.52 | 1.95 |
| Piotroski F-Score | 7 | 5 |
Calculated by StockData from Insulet's SEC filings and the latest closing price. Hover a measure to see its formula. The grey column is the median of companies in the same industry group (two-digit SIC code); green or red marks a better or worse value than that median.